Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATHS trial of low-dose aspirin in sepsis
ACTRN12616001377426Phase 2Not yet recruiting
- Sponsor
- Townsville Hospital and Health Service
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aspirin in sepsis (3 arms), sponsored by Townsville Hospital and Health Service. Primary endpoints: Effect of low-dose aspirin on aspirin-triggered lipoxin pathways and Effect of low-dose aspirin on NF-kB pathways. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
sepsis
Beyond the preview
Go deeper on ACTRN12616001377426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001377426.